Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
29 Novembro 2023 - 6:27PM
Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ:
KTTA), today announced that its annual meeting of stockholders held
on November 29, 2023 (the “Annual Meeting”) was convened and then
adjourned, without conducting any business, in order to provide
stockholders additional time within which to vote on the proposals
described in the Company’s definitive proxy statement filed with
the Securities and Exchange Commission (“SEC”) on October 26, 2023
(the “Proxy Statement”).
The adjourned Annual Meeting will reconvene on
December 19, 2023 at 9:00 a.m. Eastern Time at
www.virtualshareholdermeeting.com/KTTA2023. The original record
date of October 12, 2023 remains the same for the adjourned Annual
Meeting. Stockholders of record may attend the virtual webcast
meeting by logging in through the same method as set forth in the
Company’s Proxy Statement.
The Company has adjourned the Annual Meeting to
allow stockholders additional time to vote. All proposals set
forth in the Proxy Statement will be voted upon at the adjourned
Annual Meeting to be held on December 19, 2023. The Company’s
board of directors believes approval of each of these proposals is
the best interests of the Company and its stockholders for the
reasons described in the Proxy Statement and recommends
stockholders vote FOR all proposals.
Stockholders who have already voted their shares
on the proposals contained in the Proxy Statement do not need to
vote again. Proxies previously submitted will be voted at the
adjourned Annual Meeting, and stockholders who have previously
submitted a proxy or otherwise voted need not take any action.
Pasithea encourages all stockholders, as of the
record date on October 12, 2023, who have not yet voted to do so
promptly. Stockholders may use the Proxy Card that they were
originally provided with or vote in the manner as set forth in the
Proxy Statement.
About Pasithea Therapeutics
Corp.
Pasithea is a biotechnology company primarily
focused on the discovery, research and development of innovative
treatments for central nervous system (CNS) disorders and
RASopathies. With an experienced team of experts in the fields of
neuroscience, translational medicine, and drug development,
Pasithea is developing new molecular entities for the treatment of
neurological disorders, including Amyotrophic Lateral Sclerosis
(ALS), Neurofibromatosis type 1 (NF1), Noonan syndrome and Solid
Tumors.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements” made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include all statements,
other than statements of historical fact, regarding the Company’s
current views and assumptions with respect to future events
regarding its business, the success of the Company’s current and
future business strategies, product development, clinical studies,
clinical and regulatory timelines, market opportunity, competitive
position, business strategies, potential growth opportunities and
other statements that are predictive in nature. Forward-looking
statements are subject to numerous conditions, many of which are
beyond the control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including factors set forth in the Company’s most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and other filings made with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics
Contact
Patrick GaynesCorporate
Communicationspgaynes@pasithea.com
Pasithea Therapeutics (NASDAQ:KTTA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024